Literature DB >> 24385539

Cardiovascular risk in patients with hemophilia.

Pieter W Kamphuisen1, Hugo ten Cate.   

Abstract

Patients with hemophilia, who have a lifelong hypocoagulability, seem to have a lower cardiovascular mortality than the general population. Nevertheless, the prevalence of cardiovascular risk factors in patients with hemophilia is as prevalent as in the general population, and hypertension is even more common. Furthermore, hemophiliacs have the same degree of atherosclerosis as the general population. The reduced cardiovascular mortality may be explained by reduced thrombus formation resulting from hypocoagulability. On the other hand, hemophilia, which is associated with reduced thrombin generation, may also increase atherosclerotic plaque stability, as has been shown in mice. Because treatment of these events is extremely challenging in patients with increased bleeding tendency, detection and aggressive treatment of risk factors is mandatory.

Entities:  

Mesh:

Year:  2014        PMID: 24385539     DOI: 10.1182/blood-2013-11-453159

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

Authors:  R H Olie; P E J van der Meijden; H M H Spronk; H Ten Cate
Journal:  Handb Exp Pharmacol       Date:  2022

2.  Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.

Authors:  Reut Shnerb Ganor; Dror Harats; Ginette Schiby; David Gailani; Hanna Levkovitz; Camila Avivi; Ilia Tamarin; Aviv Shaish; Ophira Salomon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-21       Impact factor: 8.311

3.  Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study.

Authors:  Craig D Seaman; Kristen M George; Margaret Ragni; Aaron R Folsom
Journal:  Thromb Res       Date:  2016-06-02       Impact factor: 3.944

4.  Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations.

Authors:  Rita Carolina Figueiredo Duarte; Cláudia Natália Ferreira; Danyelle Romana Alves Rios; Helton José Dos Reis; Maria das Graças Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2017-05-09

5.  The coagulation system in atherothrombosis: Implications for new therapeutic strategies.

Authors:  Renske H Olie; Paola E J van der Meijden; Hugo Ten Cate
Journal:  Res Pract Thromb Haemost       Date:  2018-02-19

Review 6.  Mortality in congenital hemophilia A - a systematic literature review.

Authors:  Charles R M Hay; Francis Nissen; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

Review 7.  Cardiovascular disease in hereditary haemophilia: The challenges of longevity.

Authors:  Susan Shapiro; Gary Benson; Gillian Evans; Catherine Harrison; Sarah Mangles; Mike Makris
Journal:  Br J Haematol       Date:  2022-02-21       Impact factor: 8.615

8.  Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS).

Authors:  Neil A Zakai; Suzanne E Judd; Brett Kissela; George Howard; Monika M Safford; Mary Cushman
Journal:  Thromb Haemost       Date:  2018-06-11       Impact factor: 5.249

9.  A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusion.

Authors:  Silva Zupančić-Šalek; Marijo Vodanović; Dražen Pulanić; Boško Skorić; Irina Matytsina; Jolanta Klovaite
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.